18740-39-1|2,4-Dichlorothieno[2,3-d]pyrimidine| Ambeed

Structure of 18740-39-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 18740-39-1 ] Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 18740-39-1 ]

CAS No. :	18740-39-1
Formula :	C₆H₂Cl₂N₂S
M.W :	205.06
SMILES Code :	ClC1=NC2=C(C(=N1)Cl)C=CS2
MDL No. :	MFCD09743991
InChI Key :	HRXNGIQKOWQHCX-UHFFFAOYSA-N
Pubchem ID :	12217324

Safety of [ 18740-39-1 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H317-H319
Precautionary Statements:	P280-P305+P351+P338

Computational Chemistry of [ 18740-39-1 ] Show Less

Physicochemical Properties

Num. heavy atoms	11
Num. arom. heavy atoms	9
Fraction Csp3	0.0
Num. rotatable bonds	0
Num. H-bond acceptors	2.0
Num. H-bond donors	0.0
Molar Refractivity	47.44
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	54.02 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.22
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	3.48
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	3.0
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.85
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	3.97
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.9

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.91
Solubility	0.0253 mg/ml ; 0.000123 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-4.3
Solubility	0.0104 mg/ml ; 0.0000505 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-3.83
Solubility	0.03 mg/ml ; 0.000146 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.08 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.37

Application In Synthesis of [ 18740-39-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 18740-39-1 ]

[ 18740-39-1 ] Synthesis Path-Downstream 1~35

1
[ 18740-39-1 ]
[ 124-41-4 ]
[ 18740-40-4 ]

References: [1]Bulletin de la Societe Chimique de France,1975,p. 592 - 597.

2
[ 18740-39-1 ]
[ 141-52-6 ]
[ 18740-41-5 ]

References: [1]Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques,1968,vol. 266,p. 128 - 130.

3
[ 18740-39-1 ]
[ 139-02-6 ]
[ 56844-19-0 ]

References: [1]Bulletin de la Societe Chimique de France,1975,p. 592 - 597.

4
[ 18740-39-1 ]
[ 18740-44-8 ]

References: [1]Bulletin de la Societe Chimique de France,1975,p. 592 - 597.

5
[ 18740-39-1 ]
4-chloro-thieno[2,3-<i>d</i>]pyrimidin-2-ylamine [ No CAS ]

References: [1]Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques,1968,vol. 266,p. 128 - 130.

6
[ 18740-39-1 ]
[ 18740-38-0 ]

References: [1]Bulletin de la Societe Chimique de France,1975,p. 587 - 591.
[2]Bulletin de la Societe Chimique de France,1975,p. 592 - 597.

7
[ 18740-39-1 ]
[ 56844-22-5 ]

Yield	Reaction Conditions	Operation in experiment
63%	With ammonium hydroxide; In ethanol; at 20℃; for 48h;	<strong>[18740-39-1]2,4-dichlorothieno[2,3-d]pyrimidine</strong> (51 g, 250 mmol),28percent aqueous ammonia (94g, 750mmol a flask containing 500mL of ethanol,The reaction was stirred for 48 hours with stirring at room temperature.TLC monitors the reaction endpoint.The precipitated solid was filtered, and the ethanol was rinsed.Drying gave Compound 22-1 (29 g, yield 63percent).

References: [1]Patent: CN109020975,2018,A .Location in patent: Paragraph 0320; 0321; 0322; 0323.
[2]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 2079 - 2085.
[3]Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques,1968,vol. 266,p. 128 - 130.
[4]Bulletin de la Societe Chimique de France,1975,p. 592 - 597.

8
[ 18740-38-0 ]
[ 18740-39-1 ]

Yield	Reaction Conditions	Operation in experiment
56%	With trichlorophosphate; In N,N-dimethyl-formamide; at 115℃; for 8h;	Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (12) (2.5 g, 0.012 mol) and a drop of DMF were added to 20 mL POCl3. Heated to 115 C for 8 h. After cooling to room temperature, the reactant was added to 500 g ice-water mixture slowly. The product was filtered off and dissolved in CH2Cl2. The insoluble was filtered off and the filtrate was distilled under reduced pressure to afford 1.7g 2,4-dichlorothieno[2,3-d]pyrimidine (13). Yield: 56.0 %, 1H NMR (400 MHz, DMSO) delta 8.16 (d, J=3.4 Hz, 1H, Ar-H), 7.62 (d, J=3.4 Hz, 1H, Ar-H). ESI-MS m/z: 205.1.
56%	With N,N-dimethyl-formamide; trichlorophosphate; at 115℃; for 5h;	To 1 g of dry thieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione was added 10 g of phosphorus oxychloride,Add 1 drop of DMF catalyst, heating to 115 , the reaction 5h, the reaction is completed, the reaction slowly added to the crushed ice,While stirring vigorously,A brown solid,Filter, filter residue dissolved in 50mL of dichloromethane, to the solution by adding 1g activated carbon and 2g silica gel,Heated to 45 reflux decolorization 1h, while the hot filter, remove the solvent,Pale yellow solid,2,4-dichlorothieno [2,3-d] pyrimidine in a yield of 56.0%.
56%	With N,N-dimethyl-aniline; trichlorophosphate; In acetonitrile; at 0 - 85℃; for 24h;	Thieno[2,3-d] pyrimidine-2,4 (1H, 3H) -dione (IX-2) (5.0 g, 29.7 mmol)And 3 mL of N, N-dimethylaniline were dissolved in 30 mL of acetonitrile,It was cooled to 0 C.16 mL of phosphorus oxychloride is kept at the reaction temperature not higher than 25 C.I am dripping slowly. The reaction mixture was heated and stirred at 80-85 C. for 24 hours.The reaction solution was cooled to 15 C.,Was slowly added to 70 mL of ice water.The obtained slurry was collected by filtration,And washed with cold water (20 mL).After drying, column chromatography (elution solvent: hexane: dichloroMethane = 1: 2)3.41 g (yield 56%) of the dichloro compound (IIa-2) was obtained as gray crystals.

49%		3 g (0.018 mol) of the intermediate lib was placed in a 100 mL three-necked flask,30 mL (0.329 mol) of phosphorus oxychloride was slowly added dropwise,After 30 min addition, 2 drops of DMF were added to the reaction mixture and the reaction was heated to reflux for 8 h. The reaction was poured into 1000 g of ice water with stirring, and a large amount of orange-colored solid was precipitated. The filter cake was washed with a large amount of water and dried at 45 C for 24 hours to obtain 1.8 g of an orange solid in a yield of 49%.
41%	With trichlorophosphate; at 106℃; for 3h;Inert atmosphere;	Under a nitrogen streamThieno [2,3-d] pyrimidine-2,4 (1H, 3H) -dione (8.4 g, 50.0 mmol) and phosphoryl chlorideL), which was stirred for 3 hours at 106 C. After completion of the reaction, the organic layer was separated using ethyl acetateWater was removed using MgSO4. The solvent of the organic layer was removed, and the residue was purified by column chromatography to obtain the target compound2,4-dichlorothieno [2,3-d] pyrimidine (4.2 g, 20.5 mmol, yield 41%).
40%	With trichlorophosphate; at 116℃; for 3h;	A mixture of thieno[2,3-phiyrimidine-2,4(l//,3//)-dione (100 mg, 0.59 mmol) and phosphonyl chloride (2 mL, 21.5 mmol) was heated at 1 16 0C for 3 h. Upon completion of the reaction, the reaction mixture was poured into ice and extract with ethyl acetate 3 times. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. Purification by column chromatography, eluting with Hexanes/Ethyl Acetate (9: 1) afforded the product as a white solid (48.1 mg, 40%): 1H NMR (DMSO, 300 MHz) delta 7.6 (d, J = 6.3 Hz, IH), 8.13(d, J = 5.7 Hz, IH).
35.5%	With N,N-dimethyl-aniline; trichlorophosphate; for 16h;Reflux;	A total of 0.8 mL N,N-dimethylaniline was added to 3.0 g of thieno[2,3-d]pyrimidine-2,4-(1H,3H)-dione 6a in 20 mL POCl3. The mixture was then heated under reflux for 16 h. Excess POCl3 was removed in vacuo, and the resulting residue was treated with ice water to yield a precipitate. The solid was collected by filtration, washed with water and dried over a funnel to afford solid 7a (1.3 g, yield 35.5%). 1H NMR (400 MHz, CDCl3): delta 7.62 (d, J = 6.4 Hz, 1H), 7.43 (d, J = 6.4 Hz, 1H).
	With trichlorophosphate; at 200℃; for 2.3h;	EXAMPLE 402,4-Dichlorothieno[2,3-d]pyrimidine; The dione of Example 39 (2.6 g) was placed into a pressure vessel with phosphorus oxychloride (15 mL). The mixture was heated at 200 0C for 2.3 hours and then cooled to room temperature and concentrated under reduced pressure. Residual phosphorus oxychloride was azeotroped . twice with toluene (30 mL) under reduced pressure. The residue was partitioned between saturated aqueous sodium bicarbonate and dichloromethane. The resulting layers were separated and the organic layer was filtered through anhydrous magnesium sulfate and concentrated to dryness under reduced pressure to give 1.06 g of the title compound: MS (ESI+) for C6H2N2CI2S m/z205.0 (M+H)+. 1H NMR (400 MHz, CDCI3) delta 7.42 (d,1 H), 7.61 (d,1 H).
	With N,N-dimethyl-aniline; trichlorophosphate; In toluene; at 100℃; for 3h;	To a solution of 1H-thieno[2,3-d]pyrimidine-2,4-dione (62) (92.8 mg, 0.552 mmol) in toluene (1 mL) were added N,N-dimethylaniline (0.140 mL, 1.10 mmol) and phosphoryl chloride (0.280 mL, 3.00 mmol). The reaction mixture was warmed to 100 C and stirred for 3 h. After cooling to room temperature, H2O was added to the reaction mixture and the mixture was extracted with CHCl3. The combined organic layer was washed with brine, dried over Na2SO4, and concentrated in vacuo to give 2,4-dichlorothieno[2,3-d]pyrimidine (63). This compound was used for the next reaction without further purification.To a solution of 63 in DMF (4 mL) was added ethyl 2-(4-aminophenyl)acetate (95.2 mg, 0.531 mmol) and the reaction mixture was stirred at 65 C for 2.5 h. After cooling, H2O was added to the reaction mixture and the mixture was extracted with EtOAc. The combined organic layer was washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was chromatographed (EtOAc/hexane = 0% to 100%) to give the title compound (85.9 mg, 0.247 mmol, 45%) as a colorless solid. 1H NMR (CDCl 3) delta: 1.28 (3H, t, J = 7.4 Hz), 3.64 (2H, s), 4.18 (2H, q, J = 7.4 Hz), 7.03 (1H, d, J = 5.7 Hz), 7.21 (1H, s), 7.29 (1H, d, J = 5.7 Hz), 7.32 (2H, d, J = 8.6 Hz), 7.56 (2H, d, J = 8.6 Hz).

References: [1]Journal of Medicinal Chemistry,2011,vol. 54,p. 7815 - 7833.
[2]Bulletin of the Korean Chemical Society,2010,vol. 31,p. 2242 - 2246.
[3]European Journal of Medicinal Chemistry,2015,vol. 93,p. 64 - 73.
[4]Patent: CN106831812,2017,A .Location in patent: Paragraph 0091; 0092; 0093.
[5]Patent: JP6120311,2017,B2 .Location in patent: Paragraph 0144-0145.
[6]Patent: CN103980287,2016,B .Location in patent: Paragraph 0148; 0151; 0152.
[7]Patent: KR2015/36982,2015,A .Location in patent: Paragraph 0100-0103.
[8]Patent: WO2008/58285,2008,A2 .Location in patent: Page/Page column 45.
[9]European Journal of Medicinal Chemistry,2011,vol. 46,p. 71 - 76.
[10]Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques,1968,vol. 266,p. 128 - 130.
[11]Patent: WO2006/79916,2006,A1 .Location in patent: Page/Page column 92.
[12]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 3325 - 3328.
[13]MedChemComm,2014,vol. 5,p. 1821 - 1828.
[14]Molecules,2019,vol. 24.

9
[ 56844-43-0 ]
[ 18740-39-1 ]

References: [1]Bulletin de la Societe Chimique de France,1975,p. 592 - 597.

10
[ 18740-39-1 ]
[ 109-89-7 ]
[ 56844-23-6 ]

References: [1]Bulletin de la Societe Chimique de France,1975,p. 592 - 597.

11
[ 18740-39-1 ]
[ 62-53-3 ]
[ 56844-26-9 ]

References: [1]Bulletin de la Societe Chimique de France,1975,p. 592 - 597.

12
[ 18740-39-1 ]
[ 76872-43-0 ]

References: [1]Journal of Medicinal Chemistry,1981,vol. 24,p. 376 - 382.

13
[ 18740-39-1 ]
[ 62-53-3 ]
[ 134372-89-7 ]

References: [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2763 - 2773.

14
[ 18740-39-1 ]
[ 95-53-4 ]
[ 1027594-22-4 ]

References: [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2763 - 2773.

15
[ 18740-39-1 ]
[ 100-61-8 ]
[ 134372-88-6 ]

References: [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2763 - 2773.

Yield	Reaction Conditions	Operation in experiment
	With trichlorophosphate; In N,N-dimethyl-aniline; for 3h;	General procedure: 2,4-Dihydroxythieno[3,2-d]pyrimidine (M1) (3.38 g, 0.020 mol) was added to the reaction flask.Phosphorus oxychloride (11.6 ml, 0.127 mol) was added.N,N-dimethylaniline (7.44 ml, 0.058 mol) was added dropwise with stirring at room temperature for 3 hours under reflux.Stop heating,Pour into 100ml of ice water.Precipitating a brownish black solid,Filtering,dry,Column chromatography (petroleum ether - ethyl acetate = 3: 1) to give a pale yellow solid 2.10g,The yield was 51.2percent.

18
[ 18740-39-1 ]
4-(N-methylphenylamino)-2-<(2-methylphenyl)amino>thieno<2,3-d>pyrimidine [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2763 - 2773.

19
[ 18740-39-1 ]
N²,N⁴-Dimethyl-N²,N⁴-diphenyl-thieno[2,3-d]pyrimidine-2,4-diamine [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2763 - 2773.

20
[ 18740-39-1 ]
2-(2-Methylphenylamino)-4-(phenylamino)thieno[2,3-d]-pyrimidine hydrochloride [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2763 - 2773.

21
[ 18740-39-1 ]
2-(4-Fluoro-2-methylphenylamino)-4-(N-methylphenylamino)thieno-[2,3-d]pyrimidine hydrochloride [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1995,vol. 38,p. 2763 - 2773.

22
[ 18740-39-1 ]
[ 79041-55-7 ]

References: [1]Journal of Medicinal Chemistry,1981,vol. 24,p. 376 - 382.

23
[ 18740-39-1 ]
1,5-Dihydro-imidazo[1,2-a]thieno[2,3-d]pyrimidin-2-one [ No CAS ]

References: [1]Journal of Medicinal Chemistry,1981,vol. 24,p. 376 - 382.

24
[ 18740-39-1 ]
[ 14080-56-9 ]

References: [1]Bulletin de la Societe Chimique de France,1975,p. 592 - 597.

25
[ 18740-39-1 ]
[ 56844-24-7 ]

References: [1]Bulletin de la Societe Chimique de France,1975,p. 592 - 597.

26
[ 4651-81-4 ]
[ 18740-39-1 ]

References: [1]Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques,1968,vol. 266,p. 128 - 130.
[2]Journal of Medicinal Chemistry,2011,vol. 54,p. 7815 - 7833.
[3]European Journal of Medicinal Chemistry,2015,vol. 93,p. 64 - 73.
[4]Patent: CN103980287,2016,B .
[5]Patent: CN106831812,2017,A .
[6]Molecules,2019,vol. 24.

27
[ 18740-39-1 ]
[ 902765-99-5 ]
[ 902765-98-4 ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In tetrahydrofuran; N,N-dimethyl-formamide; at 20℃;	EXAMPLE 41 4-[4-(1 ,1 '-biphenyl-4-ylcarbonyl) piperazin-1 -yl]-2-chlorothieno[2,3d]pyrimidine; To a mixture of <strong>[18740-39-1]2,4-dichlorothieno[2,3-d]pyrimidine</strong> (Example 40, 0.4 g) in THF/DMF (20/8 mL) was added diisopropylethylamine (0.44mL) and (1,1'-biphenyl-4-yl)piperazine trifluoroacetate (0.780 g). The mixture was stirred overnight at room temperature. The mixture was then partitioned between ethyl acetate and brine. The layers were separated and the organic layer was washed four times with brine, dried over anhydrous magnesium sulfate and concentrated. EPO <DP n="95"/>"The resulting crude mixture was stirred in hot MeOH to remove impurities and the remaining solid was collected and dried to give 0.34 g of the title compound: MS (ESI+) for C23H19CIN4O1S1 m/z 435.25 (M+H)+.1H NMR (400 MHz, CDCI3). delta 3.6 to 4.2 (m, 8H) 7.3 to 7.67 (m.11 H). To a mixture of the pyrimidine of Example 40 (0.4 g) in THF/DMF (20/8 ml_) was added diisopropylethylamine (0.44 ml_) and the TFA salt of Example 15 (0.780 g). The mixture was stirred overnight at room temperature. The mixture was then partitioned between ethyl acetate and brine. The layers were separated and the organic layer was washed four times with brine, dried over anhydrous magnesium sulfate and concentrated. The resulting crude mixture was stirred in hot methanol to remove impurities and the remaining solid was collected and dried to give 0.34 g of the title compound: MS (ESI+) for C23H19CIN4OS m/z 435.25 (M+H)+. 1H NMR (400 MHz, CDCI3). delta 3.6-4.2 (m, 8H) 7.3-7.67 (m, 11H).

References: [1]Patent: WO2006/79916,2006,A1 .Location in patent: Page/Page column 92-93.

28
[ 18740-39-1 ]
[ 100-61-8 ]
2,4-Bis(N-methylphenylamino)thieno(2,3-d)pyrimidine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In dichloromethane; chloroform;	EXAMPLE 8 2,4-Bis(N-methylphenylamino)thieno(2,3-d)pyrimidine 2,4-Dichlorothieno[2,3-d]pyrimidine (2 g, 0.00975 mol) and N-methylaniline (5 ml) were heated in an oil bath at 150° for 2 hours. The reaction mixture was dissolved in chloroform (200 ml) and extracted with 2N hydrochloric acid (3*100 ml). The chloroform solution was then washed with sodium carbonate solution, dried over magnesium sulphate, filtered and evaporated to give an oil. The oil was purified by chromatography using dichloromethane as eluant. The solid obtained was recrystallized from ether/petroleum ether (b.p. 40°-60°) to give the title compound, (1.2 g) m.p. 85°-87°.
	In dichloromethane; chloroform;	Example 8 2,4-Bis(N-methylphenylamino)thieno(2,3-d)pyrimidine 2,4-Dichlorothieno[2,3-d]pyrimidine (2 g, 0.00975 mol) and N-methylaniline (5 ml) were heated in an oil bath at 150° for 2 hours. The reaction mixture was dissolved in chloroform (200 ml) and extracted with 2N hydrochloric acid (3x100 ml). The chloroform solution was then washed with sodium carbonate solution, dried over magnesium sulphate, filtered and evaporated to give an oil. The oil was purified by chromatography using dichloromethane as eluant. The solid obtained was recrystallized from ether/petroleum ether (b.p. 40-60°) to give the title compound, (1.2 g) m.p. 85-87°.

References: [1]Patent: US5280026,1994,A .
[2]Patent: EP404356,1990,A1 .

29
[ 18740-39-1 ]
[ 142-04-1 ]
[ 134372-89-7 ]

Yield	Reaction Conditions	Operation in experiment
	With aniline; In diethyl ether; ethanol;	(b) 2-Chloro-4-(phenylamino)thieno[2,3-d]pyrimidine 2,4-Dichlorothieno[2,3-d]pyrimidine (3.2 g, 0.0156 mol) and aniline (2.9 g, 0.0311 mol) in ethanol were stirred at room temperature for 20 hours. The solvent was evaporated under reduced pressure to give an oil. The oil was treated with diethyl ether to give a solid, aniline hydrochloride. The filtrate was evaporated under reduced pressure to give the product as a solid, (3.74 g). Recrystallization (0.7 g) from methanol gave a pure sample of the title compound, (0.53 g), m.p. 149°-151°.
	With aniline; In diethyl ether; ethanol;	(b) 2-Chloro-4-(phenylamino)thieno[2,3-d]pyrimidine 2,4-Dichlorothieno[2,3-d]pyrimidine (3.2 g, 0.0156 mol) and aniline (2.9 g, 0.0311 mol) in ethanol were stirred at room temperature for 20 hours. The solvent was evaporated under reduced pressure to give an oil. The oil was treated with diethyl ether to give a solid, aniline hydrochloride. The filtrate was evaporated under reduced pressure to give the product as a solid, (3.74 g). Recrystallization (0.7 g) from methanol gave a pure sample of the title compound, (0.53 g), m.p. 149-151°.

References: [1]Patent: US5280026,1994,A .
[2]Patent: EP404356,1990,A1 .

30
[ 18740-39-1 ]
[ 95-53-4 ]
2,4-Bis(N-methylphenylamino)thieno(2,3-d)pyrimidine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In dichloromethane; chloroform;	Example 9 2,4-Bis(2-methylphenylamino)thieno[2,3-d]pyrimidine 2,4-Dichlorothieno[2,3-d]pyrimidine (1.5 g, 0.0073 mol) and o-toluidine (5 ml) were heated in an oil bath at 160° for 2 hours. The reaction mixture was dissolved in chloroform (200 ml) and washed with 2N hydrochloric acid (3 x 100 ml), then sodium carbonate solution, dried over magnesium sulphate, filtered and evaporated under reduced pressure to give a solid, (1.98 g). The solid was purified by column chromatography using dichloromethane as eluant. The fractions containing the product were combined and evaporated under reduced pressure to give a solid. Recrystallization from diethyl ether/petroleum ether (b.p. 40-60°) gave the title compound, (1.0 g), m.p. 121-123°, References for starting materials

References: [1]Patent: EP404356,1990,A1 .

31
[ 18740-39-1 ]
[ 4198-90-7 ]
[ 1024603-82-4 ]

Yield	Reaction Conditions	Operation in experiment
91.7%		4-hydroxy-3,5-dimethylbenzonitrile (0.15 g, 1 mmol) and potassium carbonate (0.17 g, 1.2 mmol) were weighed in 5 mLN, N-dimethylformamide (DMF), stirred at room temperature for 15 minutes, and then 2,4-dichlorothieno [2,3-d] pyrimidine(0.21 g, 1 mmol) was added at room temperature for 2 h (TLC detection reaction was complete). At this point there is a lot of white solid generated, slowly To this was added 25 mL of ice water, filtered and dried in a vacuum oven to give the white solid as compound 4 - ((2-chlorothiophene[2,3-d] pyrimidin-4-yl) oxy) -3,5-dimethylbenzonitrile in a yield of 91.7percent
91.7%		Weigh 4-hydroxy-3,5-dimethylbenzonitrile (0.15 g, 1 mmol) and potassium carbonate (0.17 g, 1.2 mmol) in 5 mL of N,N-dimethylformamide (DMF),Stir for 15 minutes at room temperatureThen, <strong>[18740-39-1]2,4-dichlorothieno[2,3-d]pyrimidine</strong> (0.21 g, 1 mmol) was added and the mixture was stirred at room temperature for 2 h (TLC detection reaction was completed).At this time, a large amount of white solid was formed, and 25 mL of ice water was slowly added thereto, filtered, and dried in a vacuum drying oven.Obtaining a white solid is the compound 4-((2-chlorothieno[2,3-d]pyrimidin-4-yl)oxy)-3,5-dimethylbenzonitrile, yield 91.7percent.
28%		A stirred suspension of NaH (85 mg, 2.12 mmol) in dry THF (12 mL) was added 4-hydroxy-3,5- dimethyl benzonitrile (31 1 mg, 2.12 mmol) and stirred at room temperature for 30 min under Argon. The reaction mixture was added to a solution of 2,4-dichlorothieno[2,3-rf]pypimidine (434 mg, 2.12 mmol) in dry THF (10 mL) and heated at 50 0C for 2 h, the resulting mixture was diluted with water and washed with EtOAc. The combined organic layers were washed with water, brine, dried over NazSQi, filtered and concentrated in vacuo. The crude product was purified by column chromatography, eluting with hexancs/ethyl acetate (5: 1) to give the product as a white solid (188 mg, 28percent):1H NMR (DMSO, 300 MHz) delta 2.10 (s, 6H), 7.72 (d, 7= 5.7 Hz, IH), 7.75 (s, 2H), 8.02 (d, J = 6.0 Hz, IH).

References: [1]Journal of Medicinal Chemistry,2017,vol. 60,p. 4424 - 4443.
[2]Patent: CN106866699,2017,A .Location in patent: Paragraph 0059; 0060; 0061.
[3]Patent: CN108440559,2018,A .Location in patent: Paragraph 0059; 0060; 0061.
[4]Patent: WO2008/58285,2008,A2 .Location in patent: Page/Page column 46.

32
[ 18740-39-1 ]
[ 88-05-1 ]
[ 1024603-83-5 ]

Yield	Reaction Conditions	Operation in experiment
36%	With trifluoroacetic acid; In trifluoroethanol; at 90℃; for 48h;	To a solution of 2,4-dichlorothieno[2,3-phiyrimidine (805 mg, 3.94 mmol), TFA (0.91 mL, 11.82 piunol) in TFE (1 1 mL) was added 2,4,6-trimethylaniline (0.15 mg, 1.1 mmol) in a sealed tube. The reaction was stirred at 90 0C for 2 d. Reaction mixture was diluted with CH2Cl2 and washed with saturated NaHCO3 (3 x 20 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by HPLC to afford the product as a white solid (43.4 mg, 36percent):1H NMR (DMSO, 300 MHz) delta 2.08 (s, 6H), 2.27 (s, 3H), 6.97 (s, 2H), 7.69 (d, J = 6.0 Hz, IH), 7.78 (d, J = 6.0Hz, IH), 9.68 (s, IH).

References: [1]Patent: WO2008/58285,2008,A2 .Location in patent: Page/Page column 47.

33
[ 18740-39-1 ]
[ 527-60-6 ]
[ 1024603-81-3 ]

Yield	Reaction Conditions	Operation in experiment
97%		A stirred suspension of NaH (9.5 mg, 0.24 mmol) in dry THF (1 mL) was added 2,4,6-trimethyl phenol(32.1 mg, 0.24 mmol) and stirred at room temperature for 30 min under Argon. The reaction mixture was added to a solution of 2,4-dichlorothieno[2,3-rf]pyrimidine (48.1 mg, 0.24 mmol) in dry THF (1.5 mL) at 0 0C and allow it to slowly warmed up to room temperature. After stirring the reaction for 4 h, the resulting mixture was diluted with water and washed with EtOAc. The combined organic layers were washed with water, brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by column chromatography, eluting with hexanes/ethyl acetate (9: 1 ) to give the product as a white solid (71 mg, 97percent):1H NMR (DMSO, 300 MHz) delta 2.0 (s, 6H), 2.27 (s, 3H), 6.98 (s, 2H), 7.65 (d, J = 6.0 Hz, IH), 7.75 (d, J = 5.7Hz, IH).

References: [1]Patent: WO2008/58285,2008,A2 .Location in patent: Page/Page column 45.

34
[ 110-91-8 ]
[ 18740-39-1 ]
[ 63894-67-7 ]

Yield	Reaction Conditions	Operation in experiment
88.4%		A 5 L reaction vial equipped with a mechanical stirrer, internal temperature probe, and a nitrogen bubbler was charged with 2,4-dichlorothieno[2,3-d]pyrimidine (91 g.) and methanol (1.5 L). Next, morpholine (85.1 g.) was added and the reaction mixture was stirred at ambient temperature for 1-2 hours. An aliquot was taken and diluted with DCM/ ACN and analyzed by LC/MS to confirm consumption of the starting material. The reaction flask was then charged with water (3.0 L) at a rate that maintains an internal temperature below 25 C. A solid was collected by vacuum filtration and rinsed with water (500 mL). The washed solid was dried in a vacuum oven at 66 C for 24 hours to afford 2- chloro-4-morpholinotMeno[2,3-<i]pyrimidme as an off white solid (100.3 g., 88.4%). This intermediate may also be prepared by General Procedure D-2. 1H NMR (400 MHz, DMSO- d6) delta 3.736 (t, J= 4.8 Hz, 4H), delta 3.897 (t, J= 5.2 Hz, 4H), delta 7.658 (d, J= 6.4Hz, IH), delta 7.682 (t, J= 6.4Hz, 4H). LCMS (ESI pos) m/e 257 (M+l).
86.1%	at 20℃; for 1.5h;	2,4-Dichlorothieno[2,3-d]pyrimidine (13, 2.8 g, 0.014 mol) was dissolved in 20 mL CH3OH. 2.8 mL morpholine was added slowly at room temperature. Stirred for 1.5 h. The product was filtered off and dry to afford 3.1 g 4-(2-chlorothieno[2,3-d]pyrimidin-4-yl)morpholine (14). Yield: 86.1%. 1H NMR (400 MHz, DMSO) delta 7.70 (s, 1H, Ar-H), 7.69-7.65 (m, 1H, Ar-H), 3.96-3.86 (m, 4H, OCH2), 3.75 (d, J=4.4 Hz, 4H, NCH2). ESI-MS [M+H] m/z: 256.1.
86.1%	In methanol; at 20℃; for 0.5h;Cooling with ice;	1 g of 2,4-dichlorothieno [2,3-d] pyrimidine was dissolved in 20 mL of methanol, 1 mL of morpholine was added dropwise to the ice bath,Gradually rose to room temperature, reaction 0.5h, precipitation of solid, filter,A white solid,4- (2-chlorothieno [2,3-d] pyrimidin-4-yl) morpholine in a yield of 86.1%.

80%	In methanol; at 20℃; for 1h;Cooling with ice;	A mixture of 1.07 g (0.005 mol) of intermediate IIlbWas placed in 20 mL of methanol,Ice bath1 mL of morpholine was slowly added dropwise,After completion of the dropwise addition,Room temperature reaction lh,After reaction, the reaction solution was added to 100mL of ice water. A large amount of yellow solid was precipitated. The filter cake was washed with 200mL water and dried at 50 C for 5 hours to obtain 1.02g of yellow solid. The yield was 80%.
	at 20℃; for 3h;	The title compound (3.82 g, 76%) was prepared by a known methods using 2,4-dichlorothieno[2,3- d]pyrimidine (4.00 g, 19.50 mmol) and morpholine( 3.75 mL, 42.91 mmol). 1H MR (DMSO- d6): d 3.72 (t, J=4.6 Hz, 4H), 3.88(t, J= 5.0 Hz, 4H), 7.60-7.70 (m, 2H).

References: [1]Patent: WO2008/73785,2008,A2 .Location in patent: Page/Page column 170.
[2]European Journal of Medicinal Chemistry,2015,vol. 93,p. 64 - 73.
[3]Patent: CN106831812,2017,A .Location in patent: Paragraph 0094; 0095; 0096.
[4]Journal of Medicinal Chemistry,2011,vol. 54,p. 7815 - 7833.
[5]Patent: CN103980287,2016,B .Location in patent: Paragraph 0148; 0153; 0154.
[6]Patent: WO2019/113523,2019,A1 .Location in patent: Paragraph 0217.
[7]Molecules,2019,vol. 24.

35
[ 18740-39-1 ]
[ 79578-98-6 ]
[ 1220517-74-7 ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In ethanol; at 70℃;	Intermediate 7; 2-Chloro-Lambda/-(l-methyl-lH-imidazol-4-yl)thienor2,3-pipyrimidin-4-amineA mixture of 1 -methyl- lH-imidazol-4-amine (prepared from Intermediate 1 as described in the synthesis of Intermediate 10, 194 mg, 2 mmol) and <strong>[18740-39-1]2,4-dichlorothieno[2,3-d]pyrimidine</strong> (410 mg, 2.00 mmol) in ethanol (10 mL) was treated with triethylamine (0.279 mL, 2.00 mmol). The resulting mixture was heated at 700C overnight. The precipitate was filtered, and washed with ethanol. 303mg of the title product was obtained. 103496-1P1H NMR (300 MHz, MeOD) delta ppm 11.17 (s, 1 H) 8.21 (d, 1 H) 7.55 (s, IH) 7.41 (s, IH) 7.36 (d, 1 H) 3.71 (s, 3 H). LCMS: 266 [M+H]+.

References: [1]Patent: WO2010/38060,2010,A1 .Location in patent: Page/Page column 67-68.

Historical Records

Technical Information

• Alkyl Halide Occurrence • General Reactivity • Grignard Reaction • Hiyama Cross-Coupling Reaction • Kinetics of Alkyl Halides • Kumada Cross-Coupling Reaction • Reactions of Alkyl Halides with Reducing Metals • Reactions of Amines • Stille Coupling • Substitution and Elimination Reactions of Alkyl Halides • Suzuki Coupling

Related Functional Groups of
[ 18740-39-1 ]

Chlorides

A105037 [43088-67-1]

4-Chloro-5-methylthieno[2,3-d]pyrimidine

Similarity: 0.85

A630685 [137240-10-9]

4,5-Dichlorothieno[2,3-d]pyrimidine

Similarity: 0.81

A112203 [89466-59-1]

2-Chloro-4-methyl-6-(methylthio)pyrimidine

Similarity: 0.65

A212738 [89283-48-7]

4-Chloro-6-(methylthio)pyrimidine

Similarity: 0.65

A231363 [1780-31-0]

2,4-Dichloro-5-methylpyrimidine

Similarity: 0.63

Related Parent Nucleus of
[ 18740-39-1 ]

Other Aromatic Heterocycles

A105037 [43088-67-1]

4-Chloro-5-methylthieno[2,3-d]pyrimidine

Similarity: 0.85

A630685 [137240-10-9]

4,5-Dichlorothieno[2,3-d]pyrimidine

Similarity: 0.81

A181784 [14080-56-9]

Thieno[2,3-d]pyrimidin-4-amine

Similarity: 0.63

A137163 [99429-80-8]

4,6-Dichlorothieno[2,3-b]pyridine

Similarity: 0.62

A130229 [62226-18-0]

6-Chlorothieno[2,3-b]pyridine

Similarity: 0.61

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

{[proInfo.proName]}

CAS No.: 18740-39-1

{[proInfo.proName]}